Up until now, the cell therapy industry has been driven by the remarkable success of CAR T therapy. However, many believe the future of immunotherapy lies with other cell types such as NKs, Gamma Deltas, B Cells, TILs, and B cells, which offer many advantages over CAR T therapies and are attracting the attention of big pharma and investors. Cambrid
08-09 August 2023